Use of microbiome analysis as a complementary endpoint in clinical trials

Area of Science:

• Microbiology
• Pharmacology
• Clinical Medicine

Background:

• Cystic fibrosis (CF) patients often experience chronic Pseudomonas aeruginosa colonization.
• Understanding treatment effects beyond direct pathogen targeting is crucial for CF management.
• The gut and lung microbiomes play significant roles in CF pathogenesis and progression.

Purpose of the Study:

• To evaluate the safety and efficacy of oral R-roscovitine in CF patients.
• To investigate the impact of R-roscovitine on lung and gut microbial communities.
• To explore dose-dependent effects of R-roscovitine on microbiome structure and dynamics.

Main Methods:

• The ROSCO-CF study involved administering oral R-roscovitine to CF patients.
• Sputum and fecal samples were collected pre- and post-treatment.
• 16S rDNA sequencing was used to analyze microbial community composition and diversity.

Main Results:

• R-roscovitine did not directly impact Pseudomonas aeruginosa colonization.
• Microbiome alpha diversity remained stable, but beta diversity showed dose-dependent shifts.
• Specific bacterial taxa abundance changed with R-roscovitine dosage, with increased Tannerella and Granulicatella elegans, and decreased Streptococcus.

Conclusions:

• R-roscovitine may modulate the gut and lung microbiomes in a personalized, dose-dependent manner.
• Microbiome profiling can serve as a valuable exploratory endpoint in clinical trials for CF.
• Further research is warranted to elucidate the clinical implications of these microbiome alterations.